M. Takahashi et al., ASSESSMENT OF PROLIFERATING CELL NUCLEAR ANTIGEN IMMUNOSTAINING IN PAROTID TUMORS, European archives of oto-rhino-laryngology, 255(6), 1998, pp. 311-314
We evaluated the prognostic value of immunostaining proliferating cell
nuclear antigen (PCNA) by using a monoclonal antibody (PC10) in patie
nts with parotid tumors. Twenty-seven cases were studied. Immunohistoc
hemical studies were carried out on paraffin-embedded tissues from the
patients, and the PCNA index was calculated as the percentage of posi
tively staining tumor cells. The PCNA index ranged from 0.1 to 65.3%.
We divided the 27 lesions into three groups histologically: group A wi
th benign pleomorphic tumors (11 cases), group B with low-grade malign
ant tumors (5 cases), and group C with high-grade malignant tumors (11
cases). The mean PCNA index was 0.7% in group A, 2.0% in group B, and
23.1% in group C. The clinical data revealed a significantly higher l
ocal tumor recurrence and mortality rate in group C than in groups A a
nd B. We conclude that PCNA may be used as an important indicator for
determining clinical prognosis in parotid tumors.